Valion Bio, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Valion Bio, Inc. stock issued during period, value, stock options exercised for the quarter ending 2022-09-30 was $56.00K, a 0.00% change year-over-year.
- Valion Bio, Inc. stock issued during period, value, stock options exercised for the quarter ending 2021-09-30 was $56.00K.
- Valion Bio, Inc. stock issued during period, value, stock options exercised for the quarter ending 2021-03-31 was $6.00K.
- Valion Bio, Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $56.00K, a 9.68% decline from fiscal 2021.
- Valion Bio, Inc. stock issued during period, value, stock options exercised for fiscal 2021 was $62.00K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2022-12-31 | $56.00K 10-K · filed 2024-03-25 | |
| 2022-09-30 | $56.00K 10-Q · filed 2023-11-14 | |
| 2021-12-31 | $62.00K 10-K · filed 2023-03-31 | |
| 2021-09-30 | $56.00K 10-Q · filed 2022-11-14 | |
| 2021-03-31 | $6.00K 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |